In just its second week on the market, Novo Nordisk’s oral GLP-1 therapy recorded 20,371 prescriptions, up from 4,289 in week one—a 475% week-over-week surge that eclipses any previous GLP-1 product launch. For perspective, injectable GLP-1 competitors reached only about 10,000 scripts by week two at their peak. The data, sourced from traditional pharmacies, excludes direct-to-consumer channels and telehealth platforms, suggesting real adoption rates could be two to three times higher.

Novo Nordisk currently distributes its oral GLP-1 pill through over 70,000 retail locations nationwide, establishing broad access well before rival products arrive. In addition to brick-and-mortar pharmacies, significant demand is flowing through the company’s proprietary online channel—where patients pay between $149 and $249 per month—and through virtual care providers. A backlog of prior-authorization requests further hints at a pipeline of prescriptions that have yet to be logged in retail data.

The unprecedented uptake of an oral GLP-1 therapy stands to redefine patient preferences and market dynamics. Historically, injection required clinical visits and limited mass adoption; pills remove that barrier, potentially expanding the total addressable market for weight-loss treatments by 50% or more over the next three years. Competitors planning oral launches in 2026 will face entrenched patient loyalty and established distribution, placing a premium on rapid scale-up and payer agreements to capture market share.